Search research articles
Contact Us
Filters
Showing results (271-280 of 418) with videos related to
Page
of 42
Sort By:
Molecular Cancer
|
November 4, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2020
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
Patrick Schöffski, Olivier Mir, Bernd Kasper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Journal of Clinical Pharmacology
|
December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)
Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
The Lancet. Oncology
|
July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
The Lancet. Oncology
|
August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah, Ulrik Lassen, Elena Élez, et al.
British Journal of Cancer
|
August 30, 2017
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
Heikki Joensuu, Jean-Yves Blay, Alessandro Comandone, et al.
Annals of Surgical Oncology
|
November 9, 2011
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib
Antoine Italiano, Angela Cioffi, Paola Coco, et al.
International Journal of Cancer
|
March 8, 2023
Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value
Nicolas Penel, Sylvie Bonvalot, Marie-Cécile Le Deley, et al.
Page
of 42
Search research articles
Search
Showing results (271-280 of 418) with videos related to
Sort By:
Page
of 42
Molecular Cancer
|
November 4, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2020
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
Patrick Schöffski, Olivier Mir, Bernd Kasper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Journal of Clinical Pharmacology
|
December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)
Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
The Lancet. Oncology
|
July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
The Lancet. Oncology
|
August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah, Ulrik Lassen, Elena Élez, et al.
British Journal of Cancer
|
August 30, 2017
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
Heikki Joensuu, Jean-Yves Blay, Alessandro Comandone, et al.
Annals of Surgical Oncology
|
November 9, 2011
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib
Antoine Italiano, Angela Cioffi, Paola Coco, et al.
International Journal of Cancer
|
March 8, 2023
Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value
Nicolas Penel, Sylvie Bonvalot, Marie-Cécile Le Deley, et al.
Page
of 42